Table 2.
Summary of univariate statistical analyses evaluating the association of CHD1 loss or SPOP mutation with response to LHRHa and abiraterone
| Univariate HR | 95% CI | P | |
| Overall survival from diagnosis | |||
| Metastatic at diagnosis | 2.07 | 1.32–3.24 | 0.002 |
| SPOP mutation at CRPC | 0.80 | 0.46–1.38 | 0.43 |
| CHD1 negative IHC at CRPC | 0.81 | 0.42–1.58 | 0.54 |
| ERG at CRPC | 1.14 | 0.72–1.78 | 0.58 |
| Time on abiraterone | Univariate HR | 95% CI | P |
| Metastatic at diagnosis | 1.00 | 0.63–1.60 | 0.99 |
| SPOP mutation at CRPC | 0.37 | 0.20–0.69 | 0.002 |
| CHD1 negative IHC at CRPC | 0.50 | 0.25–1.02 | 0.06 |
| ERG at CRPC | 1.25 | 0.77–2.02 | 0.37 |
| Time from start LHRH to CRPC | Univariate HR | 95% CI | P |
| Metastatic at diagnosis | 2.11 | 1.36–3.28 | 0.001 |
| SPOP mutation at CRPC | 1.13 | 0.68–1.87 | 0.64 |
| CHD1 negative IHC at CRPC | 0.86 | 0.44–1.69 | 0.66 |
| ERG at CRPC | 1.16 | 0.75–1.79 | 0.52 |
| Response to abiraterone | Univariate OR | 95% CI | P |
| Metastatic at diagnosis | 0.72 | 0.29–1.80 | 0.49 |
| SPOP mutation at CRPC | 14.50 | 2.92–71.94 | 0.001 |
| CHD1 negative IHC at CRPC | 7.30 | 0.82–65.11 | 0.08 |
| ERG at CRPC | 0.71 | 0.28–1.82 | 0.47 |